IgA Nephropathy: An Interesting Autoimmune Kidney Disease

2020/10/08 by Arun Rajasekaran, Bruce A. Julian, Dana V. Rizk · 244 citations
Medicine · #Autoimmune Bullous Skin Diseases #Autoimmune disease #Biomarker #Diabetes mellitus #Disease #Endocrinology #Glomerulonephritis #Immunology #Intensive care medicine #Internal medicine #Kidney #Kidney disease #Medicine #Nephropathy #Pathology #Platelet Disorders and Treatments #Renal Diseases and Glomerulopathies

paper · open access · doi:10.1016/j.amjms.2020.10.003

published in The American Journal of the Medical Sciences 361(2), 176-194 (Elsevier BV)

openalex publication_date 2020/10/08 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Cited by

• Immune abnormalities in IgA nephropathy
• What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
• Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review
• Immunoregulation by Artemisinin and Its Derivatives: A New Role for Old Antimalarial Drugs. [europepmc]
• The Complex Interplay between Autophagy and NLRP3 Inflammasome in Renal Diseases. [europepmc]
• The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov. [europepmc]
• The Role of Inflammasomes in Glomerulonephritis. [europepmc]
• The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study. [europepmc]
• Cytokines and Production of Aberrantly O -Glycosylated IgA1, the Main Autoantigen in IgA Nephropathy. [europepmc]
• The Gut and Kidney Crosstalk in Immunoglobulin A Nephropathy. [europepmc]
• Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases. [europepmc]
• Kidney diseases. [europepmc]
• Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review. [europepmc]
• Efficacy and Safety of Plasma Exchange as an Adjunctive Therapy for Rapidly Progressive IgA Nephropathy and Henoch-Schönlein Purpura Nephritis: A Systematic Review. [europepmc]
• Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. [europepmc]
• Osteopontin as a Biomarker in Chronic Kidney Disease. [europepmc]
• Immune abnormalities in IgA nephropathy. [europepmc]
• Immunoregulatory effects of Huaier (Trametes robiniophila Murr) and relevant clinical applications. [europepmc]
• The Crosstalk between Nephropathy and Coagulation Disorder: Pathogenesis, Treatment, and Dilemmas. [europepmc]
• Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy. [europepmc]
• Targeting the Endothelin A Receptor in IgA Nephropathy. [europepmc]
• Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial. [europepmc]
• The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. [europepmc]
• An Update on Current Therapeutic Options in IgA Nephropathy. [europepmc]
• Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis. [europepmc]
• Artemisinin and its derivatives as promising therapies for autoimmune diseases. [europepmc]
• The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives. [europepmc]
• From inflammation to immune regulation: The dual nature of dietary lectins in health and disease. [europepmc]